Adult spina bifida patients less sexually active
February 1st 2007Atlanta-Sexual activity is lower and more disturbed in adult patients with spina bifida than it is in the general population, according to a recent study by researchers from the Children's Hospital of Philadelphia. Interestingly, however, this diminished sexual activity does not appear to significantly affect spina bifida patients' quality of life, researchers said at the 2006 American Association of Pediatrics Section on Urology annual meeting here.
Initiatives will support VUR, hydronephrosis research
February 1st 2007Atlanta-A study funded by the National Institutes of Health and a new registry promise to provide needed information on the incidence, prevalence, and consequences of two important urologic conditions in children: vesicoureteral reflux and prenatal hydronephrosis. Both the study and the registry were highlighted at the American Academy of Pediatrics Section on Urology annual meeting here.
Experts debate best approaches to pediatric renal surgery
February 1st 2007Atlanta-For a number of urologic conditions in adult patients, pure laparoscopic and robot-assisted laparoscopic procedures have taken urology by storm. Pediatric urology has been somewhat slower to adopt laparoscopic approaches, but many of the same questions arise in pediatric circles when arguing the relative merits and shortcomings of current laparoscopic and open surgical options: How do postoperative pain scores, operative times, and return to activities compare? What is the learning curve for laparoscopy, and does robotic assistance shorten it? In which patients, and for which indications, is one approach preferred over another?
Pediatric urologists face a challenging future
February 1st 2007Atlanta-Shifting patient and physician demographics, a rapidly changing medical marketplace, and evolving national health policies will create unique challenges for pediatric urology in the next decade, according to William J. Cromie, MD, MBA, a pediatric urologist who is CEO of Capital District Physicians' Health Plan, Inc.
Oral agent shows efficacy as second-line prostate cancer therapy
February 1st 2007New York-Satraplatin, an oral platinum analog in late-stage development as second-line chemotherapy for hormone-refractory prostate cancer, has shown encouraging results in phase III trials, said Oliver Sartor, MD, associate professor of medicine at the Lank Center for Genitourinary Oncology at Dana Farber Cancer Institute, Boston. Dr. Sartor, who reviewed phase III results of the drug at the recent Chemotherapy Foundation Symposium here, said satraplatin is one of the most promising new agents under study for hormone-refractory disease.
Successive therapies may extend survival in AIPC
February 1st 2007New York-The administration of sipuleucel-T (Provenge), an investigational immunotherapy designed to stimulate a patient's immune response, followed by docetaxel chemotherapy prolonged survival in men with asymptomatic androgen-independent prostate cancer (AIPC), according to a recently released study. Median survival in these men was 14 months longer than would have been predicted by a prostate cancer survival nomogram, said Daniel Petrylak, MD, associate professor of medicine and director of genitourinary oncology at Columbia Presbyterian Medical Center in New York.
PSA velocity predicts prostate cancer survival earlier
February 1st 2007Baltimore-PSA velocity measured 10 to 15 years prior to prostate cancer diagnosis is a significant predictor of cancer-specific survival 2 to 3 decades later, according to the results of a study published in the Journal of the National Cancer Institute (2006; 98:1521-7).
Treatment of VUR: The bar is raised, morbidity lowered
February 1st 2007The treatment paradigm for vesicoureteral reflux has undergone a significant shift in recent years. Endoscopic surgery has provided an effective, minimally invasive option that is gradually eliminating the need for prolonged antibiotic use, monitoring with voiding cystourethrograms (VCUGs), and open surgery in children with most grades and forms of VUR.
Studies show promise for new, existing prostate cancer drugs
February 1st 2007New York-Several promising agents in early stages of development may find a role in the treatment of prostate cancer, and two ongoing cooperative group trials will provide more definitive evidence about how best to use docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer (HRPC). At the Mount Sinai School of Medicine Chemotherapy Foundation Symposium here, the developments were reviewed by Noah M. Hahn, MD, assistant professor of medicine at the Indiana University Cancer Center in Indianapolis.
MRI-based imaging shows value in pediatric diagnoses
February 1st 2007Atlanta-Magnetic resonance imaging has exciting new applications in diagnosing and evaluating of pediatric urologic conditions, according to several studies presented here at the 2006 American Academy of Pediatrics Section on Urology annual meeting.
Daily NSAID use may protect against BPH, LUTS
February 1st 2007Rochester, MN-Men who take non-steroidal anti-inflammatory drugs (NSAIDs) daily have a decreased risk for developing BPH and associated lower urinary tract symptoms, according to analyses of data collected in a longitudinal population-based cohort study of aging men.
Leaders at ACGME announce retirement plans
February 1st 2007Doris Stoll, PhD, executive director of the residency review committees for urology and three other surgical specialties at the Accreditation Council for Graduate Medical Education, has retired after 17 years of service to the Council. Separately, David C. Leach, MD, executive director of the ACGME, has announced that he will retire in September 2007.
Dr. Albertsen named medical director of UConn Medical Group
February 1st 2007Urologist Peter Albertsen, MD, has been named medical director of the UConn Medical Group, a 350-member multi-specialty physician practice, and James Thornton has been named director of the 224-bed John Dempsey Hospital, creating a new leadership team for the health center’s clinical enterprise.
Sexual enhancement supplement recalled by manufacturer
February 1st 2007Ebek, Inc., is conducting a voluntary nationwide recall of its supplement product sold under the name Liviro3. Lab analysis of Liviro3 samples conducted by the FDA found the product contains the phosphodiesterase type-5 inhibitor tadalafil, making Liviro3 an unapproved drug.
Automated bladder cancer test receives FDA clearance
February 1st 2007Ikonisys Inc. has received FDA approval to market the oncoFISH bladder diagnostic application in the United States. In conjunction with the company’s proprietary Ikoniscope robotic digital microscopy platform, oncoFISH bladder enables automated testing of cells found in urine specimens to aid in the detection of bladder cancer.
Investigational drug is found effective, safe in BPH
February 1st 2007A course of the investigational drug silodosin, 8 mg once daily for 12 weeks, was superior to placebo for the relief of both obstructive and irritative symptoms in men with BPH, two phase III studies showed. Secondary endpoints included improvement in maximum urine flow.
Prostate cancer deaths down, number of cases up
February 1st 2007Early detection and treatment of prostate cancer apparently have lived up to their potential. The annual statistical report of the American Cancer Society reports that deaths in the United States from the four leading types of cancer-including prostate cancer-have decreased for the second consecutive year.
Radiation therapy combination prolongs long-term cure rate in men with PCa
January 18th 2007Three-fourths of men treated with a combination of radiation seed implants and external beam radiation therapy for prostate cancer are cured of their disease 15 years following their treatment, according to a study published in the International Journal of Radiation Oncology*Biology*Physics (2007; 67:57-64).
New drugs increase progression-free survival in advanced RCC patients
January 18th 2007Two new drugs for advanced renal cell carcinoma effectively increase progression-free survival in patients with the disease, according to separate studies published last week in the New England Journal of Medicine (2007; 356:125-34; and 115-24).
Repeated dosing of radiopharmaceutical found safe, effective in PCa patients with bone mets
January 4th 2007Repeated doses of the targeted radiopharmaceutical samarium Sm-153 lexidronam injection (Quadramet) are a safe and effective treatment option in patients with painful bone metastases secondary to prostate cancer, according to a multicenter, phase IV study published recently in the online edition of Cancer.